[Susceptibility of fungi isolated from clinical materials to voriconazole].
The objective of the study was evaluation of the susceptibility of 139 fungal strains isolated from clinical materials to Voriconazole, a new antifungal agent of the triazole group. A dilution method was used. The drug was incorporated into the culture medium at concentrations 0.1-100 mg/l. It was found out that the antifungal effectiveness of the drug varied both between various fungal genera and species, and between strains within the same species. Total inhibition of the growth of 20% of the yeast-like fungi and 23.3% of the moulds was achieved at concentration 0.1 mg/l. It was documented that the species Candida guilliermondii, C. kefyr, Saccharomyces cerevisiae and Aspergillus fumigatus, that as a rule are resistant to triazoles, were highly susceptible to Voriconazole. Dermatophytes, too, were highly susceptible to the drug, particularly Trichophyton mentagrophytes and T. rubrum. The drug at concentration 0.1 mg/l totally inhibited 73.5% of the dermatophytes, and at concentration 1 mg/l--97.0% of them after 7 day incubation. After 14 day incubation, 97.0% of the strains were also inhibited at drug concentration not exceeding 1 mg/l.
Pawlik
Bolesław
B
Zakład Mykologii Katedry Mikrobiologii Collegium Medicum UJ w Krakowie.
Szul
Agnieszka
A
Macura
Anna B
AB
D000935:Antifungal Agents / Q000494:pharmacology*; D001230:Aspergillus / Q000187:drug effects*; D002176:Candida albicans / Q000187:drug effects*; D005658:Fungi / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D016533:Mycological Typing Techniques; D011743:Pyrimidines / Q000494:pharmacology*; D014230:Triazoles / Q000494:pharmacology*; D014249:Trichophyton / Q000187:drug effects*; D065819:Voriconazole; D015003:Yeasts / Q000187:drug effects*
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole